Christopher James Stevens - 11 Feb 2026 Form 4 Insider Report for ROCKET PHARMACEUTICALS, INC. (RCKT)

Role
Chief Operating Officer
Signature
/s/ Martin Wilson, as attorney-in-fact for Christopher James Stevens
Issuer symbol
RCKT
Transactions as of
11 Feb 2026
Net transactions value
$0
Form type
4
Filing time
13 Feb 2026, 16:05:20 UTC
Previous filing
06 Aug 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Stevens Christopher James Chief Operating Officer C/O ROCKET PHARMACEUTICALS, INC., 9 CEDARBROOK DRIVE, CRANBURY /s/ Martin Wilson, as attorney-in-fact for Christopher James Stevens 13 Feb 2026 0002079768

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RCKT Common Stock Award $0 +61,963 +15% $0.000000 469,129 11 Feb 2026 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RCKT Stock Option (Right to Buy) Award $0 +93,037 $0.000000 93,037 11 Feb 2026 Common Stock 93,037 $3.24 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis.
F2 Represents RSUs, one-third (1/3) of which will become fully vested on February 11, 2027, with the remaining shares vesting in equal quarterly installments over the following two years.
F3 This option represents a right to purchase a total of 93,037 shares of the Issuer's common stock, one-third of which will become fully vested and exercisable on February 11, 2027, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer.